摘要

The identification of circulating autoantibodies against the M-type phospholipase A(2) receptor (anti-PLA(2) R) in patients with idiopathic membranous nephropathy (iMN) has been a major discovery. Anti-PLA(2) R can be measured by a commercially available test. It is suggested that measurement of anti-PLA(2) R will change the diagnostic strategy in patients with nephrotic syndrome and may guide treatment in patients with iMN. We review the available evidence and caution against the immediate injudicious use of the assay in routine clinical practice.

  • 出版日期2012-4